In this slide show we highlight some of the top news on sarcoma in 2016, including the first frontline FDA approval in 40 years, and studies on imaging in Ewing sarcoma, maintenance chemotherapy in osteosarcoma, and more.
A case study found that a patient with an inflammatory myofibroblastic tumor and a chromoplectic TPM3-ALK rearrangement that may be involved in tumorigenesis had a strong response to the ALK inhibitor ceritinib.
A trial of five rare sarcoma subtypes found that though dasatinib failed to achieve progression-free survival goals, more than half of patients with certain subtypes did have reasonably good survival outcomes.
A 37-year-old Lebanese male with no significant past medical history initially presented with an increase in abdominal girth over a few weeks with worsening shortness of breath, nausea, and intermittent vomiting.
Improvements in neoadjuvant therapy for soft-tissue sarcomas will require the development of more efficacious systemic therapies and, if possible, the performance of histology-specific, prospective, randomized clinical trials to advance the field.
We take a look back at the year in sarcoma news and research and bring you the top stories of 2016, as well as highlight a case study on a rare subtype and a review article from the journal ONCOLOGY.